Seeing Is Believing
Currently out of the existing stock ratings of Chris Shibutani, 66 are a BUY (54.1%), 51 are a HOLD (41.8%), 5 are a SELL (4.1%).
Analyst Chris Shibutani works at GOLDMAN SACHS with a stock forecast success ratio of 50.26% fulfilled within 97.23 days on average. Previously, Chris Shibutani worked at GOLDMAN.
Chris Shibutani’s has documented 237 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 11-Apr-2024.
Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $117 was fulfilled within 1 day with a profit of $21.2 (22.13%) receiving and performance score of 221.29.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
35
$10.99 (45.77%)
34
13 days ago
13/16 (81.25%)
$11.15 (46.75%)
244
Buy
39
$14.99 (62.43%)
39
1 months 1 days ago
3/7 (42.86%)
$11.76 (43.17%)
101
Sell
25
$0.99 (4.12%)
31
2 months 12 days ago
2/2 (100%)
$-5.39 (-17.74%)
86
Hold
33
$8.99 (37.44%)
33
5 months 12 days ago
3/4 (75%)
$8.82 (36.48%)
32
Buy
35
$10.99 (45.77%)
37
6 months 6 days ago
17/33 (51.52%)
$10.3 (41.70%)
172
Which stock is Chris Shibutani is most bullish on?
Which stock is Chris Shibutani is most reserved on?
What Year was the first public recommendation made by Chris Shibutani?